What medications, other than digoxin and beta‑blockers, can be used to lower heart rate?

Medications to Lower Heart Rate Other Than Digoxin and Beta-Blockers

Nondihydropyridine calcium channel blockers (diltiazem and verapamil) are the primary alternatives to beta-blockers and digoxin for heart rate control, with Class I recommendation for both acute and chronic rate control in atrial fibrillation. 1, 2

First-Line Alternative: Calcium Channel Blockers

Diltiazem and verapamil are equally effective as beta-blockers for rate control and represent the standard alternative when beta-blockers are contraindicated or ineffective 2, 3. These agents:

• Reduce resting heart rate by 3-8 beats per minute depending on dose 4
• Work rapidly when given intravenously (onset 5-30 minutes) 2
• Are the only rate-control agents associated with improved quality of life and exercise tolerance 2
• Should be preferred over beta-blockers in patients with bronchospasm or COPD 2

Critical Caveat

Avoid nondihydropyridine calcium channel blockers in patients with decompensated heart failure or reduced ejection fraction (LVEF ≤40%) as they may exacerbate hemodynamic compromise 1. In these patients, digoxin becomes the preferred non-beta-blocker option despite your exclusion criteria.

Second-Line Alternative: Amiodarone

When conventional measures fail, amiodarone can be used for rate control (Class IIb recommendation) 1, 2, 1:

• Intravenous amiodarone is reasonable when other measures are unsuccessful or contraindicated 1, 2
• Has both sympatholytic and calcium antagonistic properties that depress AV conduction 2
• Oral amiodarone may be considered when beta-blockers, calcium channel blockers, or digoxin fail to control rate 2, 1

Important Limitations

This represents off-label use in the United States and the potential benefit must be carefully weighed against considerable toxicity risks including pulmonary fibrosis, hepatic injury, and proarrhythmia 2. Reserve amiodarone for refractory cases only 5.

Combination Therapy Approach

When single-agent therapy fails, combination therapy should be considered (Class IIa) 2, 3:

• Combining a calcium channel blocker with digoxin provides synergistic AV nodal blockade
• Dose must be modulated carefully to avoid bradycardia 1, 2
• Recent evidence suggests caution with digoxin-beta-blocker combinations, which showed increased risk of major adverse cardiovascular events in the GLORIA-AF registry 6

Clinical Decision Algorithm

For patients with preserved ejection fraction (LVEF >40%):

1. First choice: Diltiazem or verapamil 3
2. If inadequate control: Add digoxin to calcium channel blocker 2
3. If still inadequate: Consider amiodarone 2, 1

For patients with reduced ejection fraction (LVEF ≤40%):

1. Beta-blockers remain first-line (despite your question's exclusion)
2. Digoxin is the primary alternative (also excluded by your question)
3. Amiodarone becomes the practical alternative when beta-blockers and digoxin are contraindicated 2, 3

For acute rate control:

• IV diltiazem or verapamil (onset 5-30 minutes) 2
• IV amiodarone if hemodynamically unstable or other measures fail 1

Special Populations

In Wolff-Parkinson-White syndrome with AF: Calcium channel blockers are contraindicated as they may accelerate ventricular response through the accessory pathway. Use procainamide or ibutilide instead 1.

In pregnancy: Beta-blockers remain preferred, but if contraindicated, calcium channel blockers can be considered with caution 7.

In COPD/asthma: Calcium channel blockers are specifically preferred over beta-blockers 2.

Evidence Quality Note

The 2024 ESC guidelines 3 and 2014 AHA/ACC/HRS guidelines 5, 8 provide the most current recommendations, consistently supporting nondihydropyridine calcium channel blockers as the primary non-beta-blocker alternative with Level B evidence. The relegation of digoxin to second-line therapy and the limited role of amiodarone for rate control are consistent across all major guidelines.